Brainomix, a U.K.-based medical imaging company focused on artificial intelligence (AI), announced Tuesday, April 3, that it has secured $9.8 million (£7 million) to help market its software for treating stroke victims throughout the world.
e-ASPECTS, which Brainomix markets as its flagship software solution, uses AI to provide “fast and standardized assessment of stroke patient CT scans.” It was developed to improve stroke treatment at a lower cost.
“Since we started as a spin-out of the University of Oxford we have become a global market leader, with our stroke decision support and workflow tools installed in many leading stroke centres in more than 16 countries,” Michalis Papadakis, Brainomix CEO, said in a prepared statement. “With this investment we will grow around the world and continuously expand Brainomix’s intelligent imaging software for acute stroke care and clinical trials.”
FDA approval for e-ASPECTS is pending.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.